Study S002062

An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03596177
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 28
Start: 2018-09-26
Primary completion: 2019-12-22
Lead sponsor: MedImmune LLC
Conditions: Diabetes Mellitus, Type II; Obesity
Interventions: DRUG:MEDI0382; DRUG:Placebo
Results posted: TRUE

Registered primary outcomes

Percent Change in Body Weight From Baseline to Day 59 [Baseline (Day 17) and Day 59]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016007	Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Golubic R, Diabetes, obesity & metabolism	2024	Randomized trial	PMID 38562018 DOI	cites ClinicalTrials.gov:NCT03596177; registry reference DERIVED:38562018